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Abstract 
To protect horses from disease, equine practitioners typically prescribe a protocol of an 
initial primary vaccination followed by a booster vaccination 3-4 weeks later. Subsequent 
boosters are given every 6-12 months depending on the pathogen of concern. Each vaccination 
incurs an additional cost and increased chance for adverse reactions. Despite wide-spread 
protocol acceptance, duration of effectiveness of vaccines in protecting horses from disease is 
not well documented.  It was hypothesized that horses vaccinated annually since birth have 
increased antibody production that remains consistent and sufficient for long-term protection 
from common diseases.   This work resulted in the development of a novel, multiplex-magnetic 
bead-based indirect immunoassay to screen sera from vaccinated adult horses to measure 
antibody levels in response to vaccine administration. Antigens tested included West Nile Virus, 
Eastern Equine Encephalitis, Western Equine Encephalitis, Equine Influenza Virus, Equine 
Herpes Virus 1 and 4, Tetanus, and 7 different Rabies antigens (3 lab and 4 wild strains). The 
developed assay was a 7-plex capture antibody, which quantified equine IgG (Immunoglobulin 
G) that binds viral antigens derived from different rabies virus strains along with pure vaccine 
samples of the 7 different antigens. A 7-point standard curve was developed to quantify the viral-
antigen reactive IgG concentration in vaccinated horse serum. Vaccinated horses increased 
serum antibody concentration for each antigen post-vaccination with the percent increase ranging 
between 34.0% for Equine Herpes Virus 4 and 257.3% for Equine Influenza Virus.  Use of the 
novel assay will provide equine veterinarians with an economical method to measure immune 
activation toward common pathogens of concern.  This methodology will provide foundation 
level information regarding antigen specific IgG concentrations that ultimately may be 
  
extrapolated to establish protective levels of immunity resulting in establishment of vaccine 
protocols.    
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Chapter 1 - Development of a multiplex bead assay to determine 
antigen specific IgG induced by vaccination in horses 
Equine vaccinations are traditionally given at 6-12 months old, followed by booster 
vaccinations every 6-12 months throughout the life span of individual animals (AAEP 2017).   
Vaccination programs are typically applied across all individuals based on existing protocols and 
exposure risk factors (AAEP 2017). Exposure risk factors include traveling, degree of contact 
with other horses, geographic location, level of activity, age, sex, and known viral outbreaks. To 
develop immunity to a disease, an initial vaccine series primes the immune system for action and 
booster vaccines induce a memory immune response (Davis 2014). Protection via the immune 
system in response to vaccination includes proliferation of antibodies and antigen-specific T 
lymphocytes capable of responding to a virus infection (Davis 2014).  Of special interest to 
veterinarians and horse owners is the immune response affiliated with adverse vaccine reactions. 
The proliferation of lymphocytes can be used as an indicator of immune status from the vaccine 
reaction, allowing for the potential to identify extant immunity levels prior to vaccination of 
horses that exhibit adverse reactions to vaccinations administered on a predefined schedule 
(Kydd 2006).  Development of a technique to quickly and accurately test immunity levels of 
horses that exhibit adverse reactions to booster vaccinations will allow owners the comfort of 
knowing their horses have safe levels of immunity without experiencing a potentially life 
threatening adverse reaction. 
Viral vaccines contain viral antigens along with nontarget antigens including tissue 
culture-derived proteins and stabilizers (Gershwin 2012). The immune response to viral antigens 
typically also includes a mounted response to the nontarget antigens (Gershwin 2012). The 
specific response is IgE (Immunoglobulin E antibodies) to nontarget antigens, which has been 
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shown to put a patient at risk for developing Type 1 hypersensitivity as these antibodies cause an 
adverse or allergic reaction to the vaccine (Gershwin 2012).  Systemic adverse reactions that 
have been documented in response to vaccine reactions range from urticaria to colic, and may be 
as severe as anaphylactic shock (Gershwin 2012).  The major component of nontarget antigens is 
bovine serum albumin (BSA), which is used in vaccines for stabilization before administration.  
Horses with a less than 40% serum IgE response to BSA, but not having a two-fold increase 
post-vaccination do not show signs of hypersensitivity following vaccination; however, horses 
with a high measure of serum IgE in response to BSA typically have a response to vaccination 
with mild to severe adverse clinical signs (Gershwin 2012). From this information, it is 
speculated that horses who express IgE in this setting may be allergic to other vaccine 
components such as gelatin and casein.  
There is a documented syndrome termed “ASIA” (autoimmune syndrome induced by 
adjuvants) that describes autoimmune/inflammatory syndrome specifically caused by adjuvants 
used in vaccines (Shoenfeld 2011). Adjuvants are used to boost an immune response in vaccines, 
with the effect accomplished by activating both the innate and adaptive immune systems 
(Shoenfeld 2011). Within the innate immunity, adjuvants augment responses by dendritic cells, 
lymphocytes, and macrophages to increase local reaction to antigens (Shoenfeld 2011). 
Adjuvants increase the protective and lasting immune response to the vaccine and may enhance 
vaccine efficacy (Shoenfeld 2011). In equine vaccines, common constituents include bovine 
serum albumin and aluminum, which can contribute to adverse reactions to vaccinations.        
In addition, horses may be more likely to suffer an adverse vaccine reaction as they age 
because it has been suggested that IgE levels increase each year that a vaccine is given, which 
likely contributes to an increase in the saturation of mast cells that increases the likelihood of a 
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hypersensitivity reaction (Gershwin 2012). Older horses (>20 years old) have greater pre-
vaccination circulating antibodies when compared to younger horses (4-12 years of age) 
(Muirhead 2009).  Conversely, younger horses have a higher anamnestic response to vaccine 
administration (Muirhead 2009).  For these reasons, Ryan (2014) suggested that it may be 
advantageous to vaccinate strategically through monitoring antibody levels rather than routinely 
administer booster vaccinations, which would help avoid serious and unnecessary adverse 
reactions.  
The need for a rapid, economical, and user-friendly diagnostic test that provides 
veterinarians with antibody titers for numerous vaccines is necessary to limit hypersensitivity 
reactions due to vaccinations and provide options for development of individual-based strategies 
for vaccine protocols. A promising approach to test antibody titers for antigens produced in 
response to vaccination is the use of fluorescent bead-based multiplex assay. In order to establish 
the microsphere bead assay for clinical application, a standard must be established that will allow 
quantification of each individual analyte and therefore, its corresponding antigen. I established a 
standard curve that could be utilized for a defined amount of equine IgG to convert mean 
fluorescent intensity to mg/dL for a given amount of antibody that was measured. The primary 
objective for the standard curve was to develop a reliable constant that corresponded to the 
antigens being evaluated for that specific plate and can be utilized with every plate. 
 Material and Methods 
 Assay Development 
Moore (2015) developed a multiplex-bead-based indirect immunoassay to screen sera 
obtained from vaccinated horses against rabies antigens isolated from 7 rabies virus isolates of 
skunks, bats, and lab strains. The technique utilized xMap technology, which employs 
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carboxylated magnetic microspheres that are distinguished by unique fluorescent spectral 
properties. Amine groups on proteins (i.e., antibodies or viral proteins) were coupled by 
carbodiimide chemistry to the xMap beads followed by incubation with test serum and then 
equine specific biotin-labeled secondary antibody and a fluorescent reporter (Figure 1.1).    
Blood samples were collected from 18 healthy adult horses on two separate occasions 
(baseline before vaccination and 14 days following booster vaccination). Thirteen of the 18 
horses had a history of prior rabies vaccination, but the other five samples were from horses with 
an unknown rabies vaccine history. Following before-vaccination blood collection, horses were 
vaccinated against rabies (Equirab, Merck). Two weeks following booster vaccination, additional 
blood was collected in aseptic fashion. Approximately 10 mL of blood samples were collected 
from the jugular vein following thorough cleaning using 70% isopropyl alcohol.  Blood samples 
were allowed to clot prior to centrifugation to obtain serum samples. Serum samples were 
aliquoted into 2-mL vials and stored at -20º C.  An individual 2-mL vial was thawed at room 
temperature for each experiment to avoid multiple freeze thaw cycles and potential protein 
denaturing.   
Antigens provided for the project were laboratory-adapted strains of rabies viruses 
included Challenge Virus Strain-11 (CVS-11), Flury-Low Egg Passage (Flury-LEP), and 
Evelyn-Rokitnici-Abelseth (ERA). Wild type rabies strains included Eastern Pipistrelle, 
Tadarida, South Central Skunk, and North Central Skunk, which were cultured from rabies-
infected brain tissue from animals that had been confirmed positive by Direct Fluorescent 
Antibody test. Rabies virus strains were genotyped by PCR sequencing (Moore 2015). 
Inactivation of the virus preparations were performed by serial passage of MNA or BHK cells 
mixed with 0.5 mL of the inactivated virus suspension and microscopic examination on each day 
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of passage for virus infected cells using fluorescent conjugated anti-rabies antibodies. No virus 
was detected in the cultured cells (Moore 2015).  
The coupling process was completed using Luminex bead coupling kit (xMAP Antibody 
Coupling Kit, Luminex, Austin, TX) to couple protein (antigens) to the microsphere beads. The 
microsphere analytes are carboxylated polystyrene microparticles, or “beads,” that have been 
dyed into spectrally distinct sets, or “regions,” allowing them to be individually identified by an 
xMAP® instrument (Baker 2012). The coupling process is a two-step carbodiimide coupling    
with sulfo-N-hydroxysulfosuccinimide (NHS) and 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC). The process was followed according to the manufacturer’s 
instructions.  
Each rabies strain was individually coupled to a specific bead, which was pre-determined 
based on the available regions that were available (Table 1.1).  Selection of each specific bead 
was determined to provide a unique spectral analysis for each antigen allowing the assay to be 
applied in a multiplex manner (i.e., 12 for CVS-11); thus, anytime the instrument read region 12 
that information would correlate with antigen CVS-11. Individual bead regions corresponded to 
emitted fluorescence detected by the Mag-Pix instrument. 
Five µg of each antigen preparation was covalently coupled to 1.0 x 106 carboxylated 
paramagnetic microspheres (beads) (MagPlex microspheres, Luminex, Austin, TX). 
Confirmation of antigen binding was determined by testing the coupled beads with mouse anti-
rabies glycoprotein (ABCam) and mouse anti-rabies nucleoprotein (Diagnostics/Millipore), and 
detected with R-PE-goat anti-mouse IgG (H+L) 2 µg/mL (Columbia Biosciences) (Moore 2015).  
The assay was performed on a MagPix instrument (Luminex, Austin, TX) using a three-
stop process (Figure 1.2). For each assay, a master mix of the analytes (beads) was made based 
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on how many antigens were being tested and how many serum samples were being evaluated.  
An equal volume containing 100 beads (using the formula C1V1=C2V2) of each specific analyte 
were mixed together with phosphate buffered saline (PBS) and 50 µLs were aliquoted to each 
well. Serum samples were serially diluted using PBS (1:125, 1:500, 1:2000, and 1:8000) to best 
determine the most useful dilution. The assay was created by combining 50 µLs of each serum 
dilution with 50 µL of the bead mix (2.5 X 106 beads/mL) in wells of a 96-well reaction plate, 
incubated overnight in the dark at 4º C on a shaker (200 rpm). After the serum was been added, a 
wash process was initiated that utilized the magnetic nature of the analytes.  The 96-well plate 
was placed on a magnetic separator for two minutes, which allowed for the magnetic analytes to 
migrate to the bottom of the well.  The excess fluid was removed and analytes were washed 
twice with 50 µLs of PBS-Tween 2%, which decreased non-specific background binding.  Once 
washing was complete, the second step was to add a secondary anti-body, which was Biotin Goat 
anti-Horse IgG at 2.0 µg/mL (Columbia Biosciences). The secondary master mix was 
determined by the number of wells being utilized on the 96-well plate (C1V1=C2V2) and the 
concentration was made using PBS.  Then 50 µLs of the master mix at the correct concentration 
was placed in each well. The plate was again incubated in the dark at 4º C on a shaker (200 rpm) 
for two hours. After two hours, the wash process was completed again. The third step was adding 
PE-Streptavidin, which is a fluorescent label at a concentration of 4.0 µg/mL (Jackson Lab). The 
mast mix was made the same way as previously described, then 50 µLs was added to each well.  
The plate was incubated in the process for one hour, and two washes were completed again.  The 
final step added 50 µLs of the driver fluid (provided by the MagPix instrument) to each well 
allowing for thorough mixing, and the plate was placed in the instrument for running.   
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The MagPix instrument utilizes two LED lights where the red LED light excited the 
fluorescent dyes in the bead itself and green light excited the fluorescent reporter (streptavidin-
Phycoerythrin) that was added in step three. The MagPix instrument expressed these data as 
mean or median fluorescent intensity.  
 Standard Curve  
Development of a standard curve required that each antigen coupled to microsphere bead 
have a corresponding standard analyte (have the same regional number that is what is read by the 
MagPix instrument). For an individual analyte, a specific area is fluorescent to express a region 
that had a corresponding number assigned to it (e.g., 15). For example, an analyte will have 
region 15 fluorescent. Region 15 was pre-determined to have the CVS-11 antigen coupled to the 
bead (described earlier in this chapter). The standard curve would additionally have the analyte 
with region 15 fluorescent; the difference would be that this antigen would be the known amount 
of equine IgG. Each of the seven vaccine antigens (results in Chapter 2) and seven rabies 
antigens (this Chapter) coupled to a microsphere analyte for the vaccine assay would have a 
corresponding standard curve microsphere analyte (i.e., there would be two region 12 beads 
where one was coupled with the CVS-11 antigen and the corresponding bead would have the 
known amount of equine IgG).    
The goal of the standard curve for the assay is to utilize a standard to be available for 
results from any equine sample tested to be computed in a graph or standard range to determine 
if titers of the patient are considered in the range of normal, healthy horses with a known vaccine 
history. The standard curve will allow for a mechanism for comparing antibody responses among 
each equine serum samples and potential of determining if the equine sample is at a protective 
level with its antibody production. 
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I followed methods outlined earlier in this chapter for coupling the known amount of 
equine IgG to the microsphere analytes (Figures 1.1 and 1.3).  The same process of running the 
assay as described above was utilized for the standard curve. Documented differences included 
that each standard analyte was coupled with 25 µg of purified mouse anti-human IgG (BD 
Biosciences) via a carboxiide reaction using the Luminex protocol that was provided (previously 
described in Chapter I). Each region that was used was coupled with 1 million microsphere beads 
(compared to vaccine antigens that were coupled with 2.5 million microsphere beads). An 
additional difference observed for the standard curve was for step 2, where there was a 7 dilution 
series of the horse reference serum with known amount of IgG. The dilution series began with 
1:1.56 – 1:100, and the dilution series was pipetted into the 96-well plate in duplicates.    
 Results 
For rabies antigen results, data generated following vaccination revealed a non-uniform 
pattern of antibody production by individual horses against various rabies strains (wild and 
laboratory strains) (Moore 2015).  All horses increased their antibody production following 
vaccination against all rabies strains that were tested (wild and laboratory strains).  The process 
successfully captured variation among individual horses.  For example, an individual horse, 
Neitto, had a low antibody response pre and post vaccination (<965 and 1,743 MFIs) suggesting 
that he had never been vaccinated against rabies prior to the present study (Figures 1.4 and 1.5).  
When comparing the wild-type strains to the laboratory strains, antibody production against the 
wild-type stain had 5-10 fold less IgG production when compared to laboratory-adapted rabies 
strains (Figures 1.6). Ten horses had a greater than 2-fold increase in antibody response to the 
rabies laboratory vaccine strains with seven of the horses had the highest antibody response to 
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the ERA strain (Figure 1.6). The additional eight horses had a one to two fold increase to the 
wild-type strain, but a specific strain was not predominate. (Figure 1.6)    
In a clinical application, the mean fluorescent intensity was converted to milligrams per 
deciliter (mg/dL) using Milliport xPonent Software when comparing the results to the standard 
curve. These results use the mean from a paired t-test of all 18 horses for each of the seven 
different rabies strains from Moore (2015). Comparison of average antibody levels in response to 
seven rabies strains in 13 horses vaccinated using rabies vaccine (Merck).  Post-vaccination 
antibody levels were greater than pre-vaccination for all rabies types (* indicates a statistical 
difference [P < 0.05]) with % increasing being a range of 62% for SCS and up to 602% for E. 
Pip (Figure 1.7).  The relative low values for the North Central Skunk (NCS) and South Central 
Skunk (SCS) results were attributed to poor passage when growing the strains and not to 
decreased immune response in the horse. The three strains highlighted in purple in Figure 1.7 are 
the lab strains of CVS-11, ERA, and Flury; the remaining strains were wild type Eastern 
Piperselle and Tadaria. The vaccine that was administered to our study group was most closely 
related to ERA. 
In addition, the assay was applied to a clinical setting to determine individual IgG 
responses in an individual horse who had a history of an adverse reaction post rabies vaccination 
and another individual with an unknown vaccine history. For comparison purposes, these horses 
were compared with H1 who was a Kansas State University owned horse with a known history 
of annual booster vaccines and therefore, served as a control. H2 was the horse with an unknown 
vaccine history. H3 was a horse with adverse vaccine reaction following a rabies booster. H1 had 
an amnestic response to all of the rabies antigens (lab strains and wild-type strains). H2 did not 
demonstrate IgG production toward rabies antigens. H3 was recently vaccinated and 
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demonstrated a marked humoral and amnestic response (Figure 1.8).  Although the horse had an 
adverse reaction to vaccination, this individual demonstrated an appropriate IgG response to 
various rabies antigens.   
 Standard Curve 
The standard curve was established as part of every plate analyzed during this project. 
The standard curve was not consistent for this project, but I was able to establish that there was 
successful coupling of the mouse anti-human IgG to each analyte as there was an increase in 
mean fluorescent intensity for each increase in concentration (Figure 1.9).  In addition, I was able 
to determine the most successful concentration of horse reference serum was 1:2000. In addition, 
the curve allowed for each individual equine patient sample to be compared to a constant (Figure 
1.10). 
Read outs that were provided using the Milliport xPonet Software provided a lower limit 
of detection and an upper limit of detection with the 7 series of dilutions of the standard curve 
between them (Figures 1.10 and 1.11). This range allows for each individual equine patient 
sample to be compared to a constant, and then compared to each other. As an example of a read 
out from MilliPort Software for one rabies analyte (Flury): from left to right the columns are - 
location on the 96-well plate, the expected ng/mL is the standard dilution factor, the mean 
fluorescent intensity for each individual well, the ng/mL is the MFI converted to ng/mL, the next 
set of MFI and ng/mL is the average of the previous values, CV (coefficient of variation) is the 
% of replication between the duplicates for each individual dilution factor (want >90%), and 
recovery is the percentage that the machine was able to recover from each well (want 100%) 
(Figure 1.12). An example of a read out from the MilliPort Software is provided for equine 
serum samples that converts the average of the duplicates from mean fluorescent intensity to a 
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clinical significant concentration where the software then compares the value to the standard 
curve, and expresses the value if below the lower limit of detection (black), if within the limit of 
detection (blue), or if above the upper limit of detection (red) (Figure 1.13).  I found that the 
standard curve was inconsistent in the range with numerous variables that affected it.   
 Discussion 
Rabies is prevalent in the environment throughout the United States with primary 
reservoirs differing based on location (i.e., skunks in the midwest or raccoons on the east coast). 
Reports from Centers for Disease Control, wild animals account for 92.6% of reported cases of 
rabies (Moore 2015). With skunks being the primary reservoir within the midwest, there are 
other reservoirs that are becoming more apparent, particularly as more research is completed to 
investigate various bat strains. As a result, the risk of exposure to horses to wild strains of rabies 
is increasing.  Thus, the primary aim of this study was to determine antibody cross reactivity of 
equine IgG following vaccination to include not only laboratory adapted strains, but also wild 
type strains.     
The primary objective of previous work (Moore 2015) was to develop a microsphere 
assay capable of determining if horses vaccinated with a commercial rabies vaccine produced 
cross reactive antibodies against the G protein of laboratory and wild strains of rabies. This assay 
was paramount and foundational for the currently reported investigations. Results from this 
primary investigation revealed that vaccinated horses produced cross reacting antibodies against 
the wild type antigens. Further, results revealed that subjects produces a higher antibody titer to 
the laboratory adapted strains of rabies that are used in vaccine production when compared to 
antibody titers against wild rabies strains. The assay allows for a high throughput using a small 
blood sample.   
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The current vaccine used for protection from equine rabies was based on one of the three 
types of laboratory strains that were passed on from Pasteur’s strains. As more strains of rabies 
are identified in nature, the question has been raised whether horses are produce cross reactive 
antibodies following routine vaccination. With the developed micro-sphere assay, Moore (2015) 
demonstrated that the immune response following vaccination differs greatly from horse to 
horse. This was attributed to variability of IgG production among individual horses following 
vaccination. In addition, results from the assay were able to verify that horses are capable of 
producing antibodies to numerous strains of rabies; this can be due to environmental exposure or 
from the vaccine booster itself. It is encouraging that the horses produced antibodies to all 7 
strains of rabies tested. 
Subsequent to the rabies vaccine investigation, the assay was extrapolated to determine 
IgG responses against equine vaccine antigens including West Nile Virus, Eastern Equine 
Encephalitis, Western Equine Encephalitis, Tetanus, Equine Herpes Virus – 1, and Equine 
Herpes Virus – 4 (Chapter 2) using similar methods as described in this chapter. The primary 
objective of the subsequent investigation was to establish an assay for routine clinical work to 
determining antibody response to numerous antigens. 
Although I was able to develop a standard curve, unfortunately, there remains some 
uncertainty in the potential application of the curve.  I consider these results to be experimental 
and preliminary, suggesting further work to conclusively establish a standard curve.  I did 
confirm the binding of mouse anti-human IgG to the microsphere beads. I also confirmed that 
with the curve and patient serums, the equine serum antibody response fit when compared to a 
known amount of equine IgG. These data allowed me to quantify if patient’s antibody levels 
were considered in danger, normal, or reactive towards a specific antigen. Future studies for 
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development of the standard curve need to explore how to make the calculations of dilutions of 
the horse reference serum more consistent, the longevity of the bead’s life, and consistent data 
with patient sample. 
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Table 1.1- Visual representation of pre-determining rabies antigens   
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Figure 1.1: A representation of the coupling process when starting with a carboxylated 
microsphere and through two reactions with a specific antigen, the microsphere ends 
the coupling process with a stable amide bond.  
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Figure 1.2 – Visual representation of the coupling process using one rabies antigen and the 
three steps that follow. (Figure provided by Kelley Black, Kansas State University)  
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Figure 1.3 - A representation of the end result of the coupling process for a capture antibody 
assay (standard curve).  (Figure provided by Kaori Knights, Kansas State University). 
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Figure 1.4 - Mean fluorescent intensity readings for 18 different horses pre-vaccination to both 
the lab-adapted strains (CVS-11, ERA, and Flury) and the wild-type strains (E.Pip, NCS, SCS, 
and Tad) 
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Figure 1.5 - Mean fluorescent intensity readings for 18 different horses post-vaccination to both 
the lab-adapted rabies strains (CVS-11, ERA, and Flury) and the wild-type strains (E.Pip, NCS, 
SCS, and Tad) 
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Figure 1.6 - Mean fluorescent intensity fold increase for all 18 horse samples post-vaccination 
for all 7 strains for rabies (CVS-11, ERA, Flury, E.Pip, NCS, Tad, and SCS) 
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Figure 1.7 - Clinical representation using milligrams/deciliter units for all 7 rabies strain (lab-
adapted strains in purple font (CVS-11, ERA, Flury) and wild-type strains in black font (E.Pip, 
NSC, SCS, and Tad)) 
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Figure 1.8 - Graphical representation of clinical significant results with horse H1 being a 
constant, H2 has an un-known vaccine history, and H3 has a history of a vaccine reaction to a 
rabies vaccine. 
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Figure 1.9 - Graphical representation of successful coupling of mouse anti-human IgG to each analyte. 
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Figure 1.10 - Single representation of a standard curve that correlates to antigen CVS-11 and is 
converting mean fluorescent intensity to nanograms/milliliter 
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Figure 1.11 - Visual representation of six separate standard beads and the graphs converting the 
mean fluorescent intensity to nanograms/milliliter 
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Figure 1.12 - Visual representation of the data that correlates to the graphical representation that 
is converting mean fluorescent intensity to a clinical significant concentration. 
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Figure 1.13- A visual representation of the results in duplicates of two equine serum samples 
(Nacho and Fargo) being converted from mean fluorescent intensity to a clinical significant 
concentration (ng/ml) 
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Chapter 2 -  Determination of Vaccine Antigen Specific IgG 
Expression Following Vaccination Using a Multiplex Microsphere-
Based Assay  
 Introduction:  
Equine vaccination is a routine component of preventative health care for horses.   
Vaccine protocols are typically initiated between 4 and 6 months of age. Equine vaccination 
protocols are based on the recommendations made by the American Association of Equine 
Practitioners (AAEP) Biological and Therapeutic Agents Committee. The AAEP recommends 
that all horses annually receive a set of core vaccines, which are West Nile Virus, Eastern Equine 
Encephalitis, Western Equine Encephalitis, Tetanus, and Rabies. In addition, there are numerous 
risk-based vaccines for additional diseases that can be given to the horse based on where it is 
traveling, if there is a potential for exposure, or an outbreak has occurred (Balaysuria 2017). 
Veterinarians are constantly questioned whether there is a need to vaccinate individual horses for 
all pathogens.  An added common question includes, why a horse should require rabies 
vaccination annually when canine vaccines protocols are for every 3 years (following initial 
series) (Harvey 2016).  One reason that horse owners are reluctant to implement extensive 
vaccine programs involves an ever growing concern for potential adverse reactions that may be 
directly related to vaccinations.   
 Vaccine reactions can occur under a variety of settings. Reported adverse reactions range 
from swelling at the injection site, swelling and stiffness through the neck, or urticaria. 
(Gershwin 2012). Other concerns of owners involve the cost of vaccines, and owners questioning 
why their horse needs to receive booster with vaccination every 6-12 months. Normally, the 
30 
vaccine protocol for a horse includes a 5-way vaccine that protects against Influenza, Tetanus, 
Eastern Equine Encephalitis, Western Equine Encephalitis, and West Nile Virus along with 
annual vaccination for Rabies. When a horse has a vaccine reaction, it is hard to determine which 
specific antigen caused the reaction as the vaccine itself contains up to five different antigens and 
usually given with a Rabies vaccination.  Typically, veterinarians give the 5-way vaccination and 
Rabies on different sides of neck, which allows veterinarians to narrow down causes of injection 
site reactions.  
 Having the ability to use a serum sample and a rapid, inexpensive laboratory test to 
determine which vaccine component is causing the reaction will help determine subsequent 
vaccine recommendations. The opportunity for veterinarians to take a serum sample from a horse 
and know the titer values for up to 14 different vaccines is immensely helpful for development of 
vaccination protocols for individual horses. Veterinarians would be able to follow titer patterns 
on an individual horse, determine which antigen the horse is having a reaction to, or save their 
clients’ money if the titers are considered within normal limits for the antigen with an assay 
system that provides a cost effect option along with the ability to have high throughput.  
 Multiplex bead assay technology previously reported by Moore (2015) demonstrated that 
a currently applied rabies vaccination in the equine industry was able to elicit an antibody 
response against wild-type strain rabies found in the environment (Chapter I).  It was the aim of 
this investigation to determine if this technology could be applied to other vaccine antigens. 
Zoetis generously provided 7 different antigens from their vaccine set for me to perform this 
assay. These antigens included: West Nile Virus (WNV), Easter Equine Encephalomyelitis 
(EEE), Western Equine Encephalomyelitis (WEE), Tetanus antigen, Influenza antigen, Equine 
Herpes Virus 1 and 4.  The primary objective was to create an assay that would detect changes in 
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antibody expression in response to vaccination among healthy horses with known vaccine 
history.  
 Material and Methods 
 Twenty two adult horses were used in the study. Ten horses from the Kansas State 
University teaching herd while twelve were privately owned. Three additional horses were 
included based on having adverse vaccine reactions. Twenty one of the twenty two horses had a 
history of annual vaccinations. Blood samples were collected on the day of vaccination as 
described in Chapter I.   Blood samples were stored at -20° C after clotting and serum being 
aliquoted.  
  Seven different inactivated vaccine antigens were provided by Zoetis and seven different 
rabies antigens provided from a previous study (Chapter I, Moore 2015) were also used with the 
assay development. The coupling process of the antigens to the beads was as previously 
described in Chapter 1, but at this time each individual antigen was bound using 20 µg of each 
virus. To confirm antigen coupling to the beads, the beads were incubated with an anti-antigen 
(for example WNV or Tetanus). (Table 2.1) There was successful coupling for West Nile Virus 
and Tetanus as the Mag-Pix instrument provided mean fluorescent intensity.    
Previous experiments that were described previously used the same indirect 
immunoassay as performed for the rabies antigens (Moore 2015). All assays were performed on 
a Mag-Pix instrument (Luminex) and measured in mean fluorescent intensity. The same process 
of coupling and steps of assay were the same as previously described in Chapter 1. The 
incubation periods between each step did change. The first and second incubation (after adding 
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equine serum and secondary anti-body) was at room temperature on a plate shaker (200 rpm) for 
one hour, and the last incubation with the fluorescent tag was only for 30 minutes.    
For assay development, an intra-assay and inter-assay were performed and calculated 
using coefficient of variation (mean of the population). The intra-assay assessed two equine 
samples in duplicates on the same 96-well plate in the first column and the last column. The 
optimal coefficient of variation for an intra-assay is <10%; all of results reached that optimal 
percentage. The inter-assay used the same equine samples in duplicates on two different plates at 
two different run times. The optimal coefficient of variation is <30% for the inter-assay. For the 
vaccine antigens, both horse one and two were below optimal coefficient of variation, but horse 
2 for the rabies antigens was above the optimal coefficient of variation. (Figures 2.1 and 2.2)  
 Results 
 Horses were vaccinated in routine fashion and demonstrated a significant increase in 
vaccine antigen specific IgG responses post vaccination (Figure 2.3). Of note, the most robust 
amnestic response was observed following vaccination with tetanus and the lowest amnestic 
response was to EIV. The pre-vaccination graph has the highest limit of the mean fluorescent 
intensity of 40,000 while the post-vaccination graph reaches up to 50,000.  Statistical analysis of 
the results was non-parametric data and used Wilcoxin Signed Rank test, and the results were 
that all seven antigens were significant (P < 0.05) post vaccination (Figure 2.4). The percentage 
differences for all 22 horse pre to post vaccination were EEE – 102%, EHV-1 – 52%, EHV-4 – 
93%, EIV – 78%, TET – 310%, WEE – 84%, and WNV- 69%. 
 In a clinical application, the assay was used to evaluate clinical relevant equine 
samples where one had an unknown vaccine history and the other had had a vaccine reaction 
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post rabies vaccination and a third equine sample with a known vaccine history was added as a 
control. Horse 1 (H1) was a control that had a known vaccine history and was boostered yearly 
with titers that were considered within normal limits. Horse 2 (H2) was a horse with an unknown 
history of vaccination. H3 was a horse with a demonstrated adverse vaccine reaction and the 
owners were considering foregoing vaccinations if the antibody titers were within normal limits. 
H1 has an amnestic immune response to all antigens demonstrating a previous vaccine booster 
history. H2 has a low amnestic response, and does not appear to have been vaccinated for any of 
the vaccines. Recommendation for H2 would be a vaccine with a booster in two to three weeks. 
H3 has a decreased amnestic response when compared to H1, and recommendation would be 
booster of all antigens. As this is the horse who had a previous vaccine history, precautions 
would be recommend such as administering flunxin meglumine before vaccination or to spread 
vaccines out over two to three weeks.  
 Discussion 
 Within the literature, it has been suggested that the focus of the equine industry should be 
transitioning to strategic vaccinating over routine vaccinating (Muirhead 2009) For this to 
become a reality, an assay needs to be developed that was economical, high throughput, and user 
friendly (Baker 2012). The assay developed using microsphere beads will allow for up to 30 
samples to be tested at once, with results within 8 hours. With the establishment of the standard 
curve (Chapter II), this provides a constant for each batch that is completed allowing for 
congruency for the assay.  
 Another main focus is increasing reports of vaccine reactions (Ryan 2014). For horses 
exhibiting a reaction post-vaccination, this assay would allow for a small volume of serum to be 
assessed whereby the resulting titers can be compared to the standard curve to determine which 
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vaccine is causing the reaction. In addition, pre-vaccination titers can be evaluated and when 
compared against the standard curve, a strategic vaccine plan can be developed. Vaccine 
reactions can be due to adjuvants that are in a vaccine along with the specific antigens (Gershwin 
2012)); thus, more work needs to be developed to look into IgE responses to the adjuvants that 
are commonly used in equine vaccines.   
 Conclusion 
.   The assay is novel and has the potential of providing beneficial information regarding 
antibiotic titers to veterinarians to improve treatment of horses subject to vaccine reactions.  In 
addition, this assay will assist with the development of further understanding of effective levels 
of vaccines and duration of vaccine effects. Future work for the assay includes testing 
functionality of the antibodies along with quantity, establishing protective level values for each 
antigen, and establishing more data that involves immune-compromised horses or horses that 
have had a history of vaccine reactions.  
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Analyte 15 (Tetanus Toxoid) 12 (WNV) 
Anti - WNV 41 MFI
Anti-Tetanus 449 MFI
Table 2.1 – MFI readings of anti-WNV and anti-tetanus against antigen 
coated analytes 
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Figure 2.1 – Intra-assay using coefficient of variation to determine accuracy of the assay within 
a single plate.  
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Figure 2.2 – Inter-assay using percent of coefficient of variation looking at accuracy between 
two separate plates.  
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Figure 2.3 – Graphical representation of all 7 antigens (WNV, WEE, EHV-4, EHV-1, EIV, and EEE) 
plus Bovine Serum Albumin pre and post-vaccination. 
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Figure 2.4 - Clinical representation using milligrams/deciliter units for all 7 vaccine antigen 
strains  
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Figure 2.5 – Graphical representation of one equine sample that had an un-known vaccine 
history and one equine sample that had a previous vaccine reaction.  
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